Dr. Rugo on Findings of Oral Paclitaxel With Encequidar in Metastatic Breast Cancer

Hope S. Rugo, MD
Published: Wednesday, Jan 08, 2020



 
Hope S. Rugo, MD, a professor in the Department of Medicine, Hematology/Oncology, and director, Breast Oncology and Clinical Trials Education, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses results of a randomized phase III  trial evaluating oral paclitaxel with encequidar in patients with metastatic breast cancer.

Patients who were enrolled on the study could not receive a taxane as their most recent prior therapy. Results showed that patients did showcase a higher response rate to receiving OPE when compared with intravenous paclitaxel. Additionally, there was a decrease in severity of alopecia and neuropathy.

In conclusion, Rugo said that the early analysis showcased a trend toward overall survival (OS) favoring patients who received OPE.

 
SELECTED
LANGUAGE


 
Hope S. Rugo, MD, a professor in the Department of Medicine, Hematology/Oncology, and director, Breast Oncology and Clinical Trials Education, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses results of a randomized phase III  trial evaluating oral paclitaxel with encequidar in patients with metastatic breast cancer.

Patients who were enrolled on the study could not receive a taxane as their most recent prior therapy. Results showed that patients did showcase a higher response rate to receiving OPE when compared with intravenous paclitaxel. Additionally, there was a decrease in severity of alopecia and neuropathy.

In conclusion, Rugo said that the early analysis showcased a trend toward overall survival (OS) favoring patients who received OPE.

 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x